(Oxymorphone Hydrochloride Injection, USP) CII
(Oxymorphone Hydrochloride Suppositories, USP)
NUMORPHAN (oxymorphone hydrochloride, USP), a semi-synthetic opioid substitute for morphine, is a potent analgesic.
NUMORPHAN Suppository is indicated for the relief of moderate to severe pain.
NUMORPHAN Injection is indicated for the relief of moderate to severe pain. It is also indicated for preoperative medication, for support of anesthesia, for obstetrical analgesia, and for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction.
Media Articles Related to Numorphan (Oxymorphone)
New Bill to Put 7-Day Limit on Pain Med Prescriptions
Source: Medscape Anesthesiology Headlines [2017.04.19]
Following similar action by several states, two US senators have introduced bipartisan legislation that would limit initial opioid prescription for acute pain to 7 days.
Medscape Medical News
Structural Pathology Not Related to Knee Pain and Function
Source: Medscape Anesthesiology Headlines [2017.04.19]
A new study found that structural knee pathologies were not associated with patient-reported symptoms among those undergoing arthroscopic meniscal surgery.
British Journal of Sports Medicine
Study paints somber picture of US mental health status and access to care
Source: Psychology / Psychiatry News From Medical News Today [2017.04.19]
More Americans than ever before suffer from serious psychological distress, and the country's ability to meet the growing demand for mental health services is rapidly eroding.
CardioBrief: Single Blood Test May Rapidly Rule Out MI in Chest Pain for Some Patients
Source: MedPage Today Emergency Medicine [2017.04.17]
(MedPage Today) -- New high-sensitivity troponin tests may ease perpetual ED dilemma
Spinal manipulation treatment for low back pain associated with modest improvement in pain, function
Source: Bones / Orthopedics News From Medical News Today [2017.04.14]
Among patients with acute low back pain, spinal manipulation therapy was associated with modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms...
Published Studies Related to Numorphan (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.
Clinical Trials Related to Numorphan (Oxymorphone)
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Terminated]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) [Completed]
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions [Completed]
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone
hydrochloride extended-release tablets (Sandoz) with Opana extended release oxymorphone
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects [Recruiting]
Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Oxymorphone Hydrochloride 10
mg Tablets under fasting conditions